OpenAI’s Wild Week: A Custom Chip, 40% of the World’s DRAM, and a $500 Million Bet to Kill the Common Cold
OpenAI designs custom chip, secures DRAM supply, invests $500M in biotech.
“Three things happened to OpenAI last week. The company went from being a model lab to something closer to a vertically integrated empire that wants…”
Why it matters
Weekly Silicon's editorial model scored this 5.95/10 overall, reading it above all as an industry story with cross-cutting implications. Its strongest dimension is regional relevance at 8/10 — direct impact on US technology hubs rather than a purely overseas development — with economic impact close behind at 7/10, pointing to meaningful consequences for capital, capacity, or competition across the industry. The impact is global rather than tied to one US hub, so the thing to watch is how it filters into domestic supply chains and hiring.
Derived from the AI score breakdown below.
AI score breakdown
A composite of 5.95/10 put this story at #7 for Tuesday, June 30, 2026, driven mostly by regional relevance (8/10) and economic impact (7/10).
Composite is the weighted sum of the five dimensions. How scoring works →
Companies in this story
Related stories
- OpenAI Soft-Releases GPT‑6 Astra · 2026-09-05
- OpenAI rolls out GPT-6 Astra, and Greg Brockman says AGI has arrived · 2026-09-04
- AGI is whatever you want it to be · 2026-09-04
- Rogue OpenAI agents appear to have organized another attack using a German wiki · 2026-09-04
- OpenAI's GPT-6 Astra on ARC-AGI-3 · 2026-09-04